Iain B McInnes1, Peter Nash2, Christopher Ritchlin3, Ernest H Choy4, Steve Kanters5, Howard Thom6, Kunal Gandhi7, Luminita Pricop8, Steffen M Jugl9. 1. University of Glasgow, Institute of Infection, Immunity & Inflammation, College of Medical, Veterinary & Life Sciences, University of Glasgow, Sir Graeme Davies Building, 120 University Place, Glasgow G12 8TA, UK. 2. Department of Medicine, University of Queensland, Brisbane, QLD 4072, Australia. 3. Division of Allergy, Immunology & Rheumatology, University of Rochester, 601 Elmwood Avenue, Box 695, Rochester, NY 1464, USA. 4. Institute of Infection & Immunity, Cardiff University School of Medicine, Tenovus Building, Heath Park Campus, Cardiff CF14 4XN, UK. 5. Precision Xtract, 1505 West 2nd Avenue, Suite 300, Vancouver, BC V6H 3Y4, Canada. 6. Bristol Medical School: Population Health Sciences, University of Bristol, Canynge Hall, 39 Whatley Road, Bristol BS8 2PS, UK. 7. Oncology Global Development Unit, Novartis Pharmaceuticals Corporation, One Health Plaza, Building 337, B04.3B, East Hanover, NJ, USA. 8. Immunology & Dermatology Franchise, Novartis Pharmaceuticals Corporation, One Health Plaza, Building 337, B04.3B, East Hanover, NJ, USA. 9. Global Patient Access Immunology & Dermatology, Novartis Pharma AG, Asklepios 8-1.001.11, Postfach, Basel, CH-4001, Switzerland.
Abstract
AIM: A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic Arthritis Response Criteria [PsARC] response rates) at 12-16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab. PATIENTS & METHODS: Trials were identified by systematic review. Separate networks were developed for the full-study populations, biologic-naive patients and biologic-experienced patients. RESULTS: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. CONCLUSION: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive network meta-analysis demonstrated superiority to placebo.
AIM: A network meta-analysis using randomized controlled trial data compared psoriatic arthritis (PsA) outcomes (American College of Rheumatology [ACR], Psoriasis Area Severity Index [PASI] and Psoriatic Arthritis Response Criteria [PsARC] response rates) at 12-16 weeks for secukinumab, adalimumab, apremilast, certolizumab, etanercept, golimumab, infliximab and ustekinumab. PATIENTS & METHODS: Trials were identified by systematic review. Separate networks were developed for the full-study populations, biologic-naive patients and biologic-experienced patients. RESULTS: In the full populations, secukinumab, adalimumab, golimumab and infliximab demonstrated the highest ACR response rates. Secukinumab and infliximab demonstrated the highest PASI response rates, and infliximab and etanercept demonstrated the highest PsARC response rates. CONCLUSION: In the full populations, secukinumab demonstrated good efficacy across all outcomes. All treatments for active PsA included in this comprehensive network meta-analysis demonstrated superiority to placebo.
Authors: Philip Mease; Ernest Choy; Peter Nash; Chrysostomos Kalyvas; Matthias Hunger; Luminita Pricop; Kunal K Gandhi; Steffen M Jugl; Howard Thom Journal: Eur J Rheumatol Date: 2018-07-01
Authors: Philip J Mease; Josef S Smolen; Frank Behrens; Peter Nash; Soyi Liu Leage; Lingnan Li; Hasan Tahir; Melinda Gooderham; Eswar Krishnan; Hong Liu-Seifert; Paul Emery; Sreekumar G Pillai; Philip S Helliwell Journal: Ann Rheum Dis Date: 2019-09-28 Impact factor: 19.103